Hostname: page-component-6898cfcb55-th4rj Total loading time: 0 Render date: 2026-11-11T12:39:47.231Z Has data issue: false hasContentIssue false
  • English
  • Français

Incidence of Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella Infections in the United States: A Systematic Literature Review

Published online by Cambridge University Press:  31 July 2017

Jennifer McDanel,
Marin Schweizer,
Victoria Crabb,
Richard Nelson,
Matthew Samore,
Karim Khader,
Amy E. Blevins,
Daniel Diekema,
Hsiu-Yin Chiang and
Rajeshwari Nair
...Show all authors
Jennifer McDanel*
Affiliation:
Department of Internal Medicine, University of Iowa, Iowa City, IowaIowa City Veteran Affairs Medical Center, Iowa City, IowaDepartment of Epidemiology, University of Iowa, Iowa City, Iowa
Marin Schweizer
Affiliation:
Department of Internal Medicine, University of Iowa, Iowa City, IowaIowa City Veteran Affairs Medical Center, Iowa City, IowaDepartment of Epidemiology, University of Iowa, Iowa City, Iowa
Victoria Crabb
Affiliation:
Iowa City Veteran Affairs Medical Center, Iowa City, IowaDepartment of Epidemiology, University of Iowa, Iowa City, Iowa
Richard Nelson
Affiliation:
Department of Clinical Epidemiology, University of Utah, Salt Lake City, UtahVeterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah
Matthew Samore
Affiliation:
Department of Clinical Epidemiology, University of Utah, Salt Lake City, UtahVeterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah
Karim Khader
Affiliation:
Department of Clinical Epidemiology, University of Utah, Salt Lake City, UtahVeterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah
Amy E. Blevins
Affiliation:
Hardin Library for the Health Sciences, University of Iowa, Iowa City, Iowa.
Daniel Diekema
Affiliation:
Department of Internal Medicine, University of Iowa, Iowa City, Iowa
Hsiu-Yin Chiang
Affiliation:
Department of Internal Medicine, University of Iowa, Iowa City, Iowa
Rajeshwari Nair
Affiliation:
Department of Internal Medicine, University of Iowa, Iowa City, IowaIowa City Veteran Affairs Medical Center, Iowa City, Iowa
Eli Perencevich
Affiliation:
Department of Internal Medicine, University of Iowa, Iowa City, IowaIowa City Veteran Affairs Medical Center, Iowa City, IowaDepartment of Epidemiology, University of Iowa, Iowa City, Iowa
*
Address correspondence to Jennifer McDanel, MS, PhD, 200 Hawkins Dr, C52-J GH, Iowa City, IA 52242 (jennifer-mcdanel@uiowa.edu).
Rights & Permissions [Opens in a new window]

Abstract

BACKGROUND

Despite a reported worldwide increase, the incidence of extended-spectrum β-lactamase (ESBL) Escherichia coli and Klebsiella infections in the United States is unknown. Understanding the incidence and trends of ESBL infections will aid in directing research and prevention efforts.

OBJECTIVE

To perform a literature review to identify the incidence of ESBL-producing E. coli and Klebsiella infections in the United States.

DESIGN

Systematic literature review.

METHODS

MEDLINE via Ovid, CINAHL, Cochrane library, NHS Economic Evaluation Database, Web of Science, and Scopus were searched for multicenter (≥2 sites), US studies published between 2000 and 2015 that evaluated the incidence of ESBL-E. coli or ESBL-Klebsiella infections. We excluded studies that examined resistance rates alone or did not have a denominator that included uninfected patients such as patient days, device days, number of admissions, or number of discharges. Additionally, articles that were not written in English, contained duplicated data, or pertained to ESBL organisms from food, animals, or the environment were excluded.

RESULTS

Among 51,419 studies examined, 9 were included for review. Incidence rates differed by patient population, time, and ESBL definition and ranged from 0 infections per 100,000 patient days to 16.64 infections per 10,000 discharges and incidence rates increased over time from 1997 to 2011. Rates were slightly higher for ESBL-Klebsiella infections than for ESBL-E. coli infections.

CONCLUSION

The incidence of ESBL-E. coli and ESBL-Klebsiella infections in the United States has increased, with slightly higher rates of ESBL-Klebsiella infections. Appropriate estimates of ESBL infections when coupled with other mechanisms of resistance will allow for the appropriate targeting of resources toward research, drug discovery, antimicrobial stewardship, and infection prevention.

Infect Control Hosp Epidemiol 2017;38:1209–1215

Information

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 38 , Issue 10 , October 2017, pp. 1209 - 1215
Copyright
© 2017 by The Society for Healthcare Epidemiology of America. All rights reserved 

Since the late 1980s, infections caused by extended-spectrum β-lactamase (ESBL)-producing organisms have been reported worldwide.Reference Jacoby, Medeiros, O’Brien, Pinto and Jiang 1 – Reference Bell, Turnidge, Gales, Pfaller and Jones 8 Patients infected with ESBL-producing E. coli or Klebsiella can have poor outcomes due to delays in receiving appropriate antimicrobial therapy and limited treatment options. Strains harboring ESBLs are resistant to third-generation cephalosporins, extended-spectrum penicillins, and monobactams.Reference Einhorn, Neuhauser, Bearden, Quinn and Pendland 9 , Reference Rice 10 Additionally, many ESBL-producing strains of E. coli and Klebsiella demonstrate coresistance to other antimicrobial agents such as fluoroquinolones, aminoglycosides, and tetracyclines.Reference Pitout 11

Trends among surveillance studies suggest an increase in the proportion of ESBL-producing strains among isolates collected from E. coli or Klebsiella infections.Reference Jones, Biedenbach and Gales 12 – Reference Karlowsky, Jones, Mayfield, Thornsberry and Sahm 15 However, the incidence of E. coli or Klebsiella infections caused by ESBL-producing strains in the United States is unclear. Knowledge of the incidence and trends of ESBL infections will aid in directing appropriate empiric therapy for patients suspected of having ESBL-E. coli or ESBL-Klebsiella infections and will promote prevention efforts in places with high incidence of these resistant organisms. We performed a systematic literature review to identify the incidence and trends of ESBL-E. coli or ESBL-Klebsiella infections in the United States from 2000 to 2015.

METHODS

Search Strategy

MEDLINE via Ovid, Cochrane Library Databases via Wiley, Cumulative Index to Nursing and Allied Health Literature via the Elton Bryson Stephens Company (EBSCO), Scopus, National Health Service Economic Evaluation Database and Web of Science were searched by a health sciences librarian to identify papers published from January 2000 to July 2014 for articles pertaining to the incidence of ESBL-E. coli or ESBL-Klebsiella infections. The searches were rerun in August of 2015 to identify studies published in the interim. The librarian used terms associated with ESBL; created a filter for incidence, prevalence, and mortality using a pre-established incidence/prevalence search filter (http://www.systematicreviewsjournal.com/content/2/1/68); and used a pre-established filter to identify economic studies (http://www.cadth.ca/media/pdf/H0490_Search_Filters_for_Economic_Evaluations_mg_e.pdf). A list of all search terms is provided in Online Supplemental Appendix 1. Additionally, reference lists from retrieved articles and reviews were examined for relevant studies that were not identified in the initial literature searches.

Inclusion and Exclusion Criteria

Included studies provided information on the incidence of ESBL-E. coli or ESBL-Klebsiella infections published between January 2000 and August 2015 and included the year 2000 or later within their study period. Only multicenter studies (≥2 centers) were included to accurately determine the incidence of ESBL infections within the US population because single-center studies were more likely to represent outbreaks. Studies that provided the number of patients with an ESBL infection and a denominator that included both infected and uninfected patients such as patient days, device days, number of admissions, or number of discharges were included. Studies that provided denominators that only included patients who were infected with non-ESBL organisms were excluded. Additionally, articles were excluded that were not written in English, contained duplicated data, or pertained to ESBL organisms from food, animals, or the environment. Institutional review board approval was not required for this systematic literature review.

Data Extraction and Quality Assessment

Titles, abstracts, and manuscripts were screened by 1 investigator (J.M. or V.C.) for inclusion in the systematic literature review. Moreover, 2 investigators independently abstracted data for included studies. Disagreements were reexamined by both investigators and were resolved by consensus. Reviewers abstracted data on study design, study population, year, number of patients, description of denominator, definition of ESBL, organism examined, inclusion and exclusion criteria, and an assessment of the potential risk of bias for cohort studies using the Newcastle Ottawa score (Online Supplemental Appendix 2).Reference Stang 16

RESULTS

Article Review

Among the 51,419 studies identified for possible inclusion in the systematic review, 605 were further assessed through manuscript review. Most studies did not meet the inclusion criteria based on the title or abstract of the study. Finally, 9 studies were included, and 596 studies were excluded (Figure 1).

FIGURE 1

Flow diagram of searched studies.

Table 1 provides a summary of the 9 included studies.Reference Freeman, Sexton and Anderson 17 – Reference Swami, Liesinger, Shah, Baddour and Banerjee 25 Among the 9 studies, 7 were observational studies and 2 were interventional studies. The interventions included screening urine cultures with E. coli or Klebsiella for ESBLReference Han, Bilker and Nachamkin 18 and restricting the use of ceftazidime and ceftriaxone.Reference Lipworth, Hyle and Fishman 22 Furthermore, 6 studies evaluated the incidence of ESBL-producing E. coli and Klebsiella among hospital-onset infections, and 2 studies evaluated the incidence among community-onset infections.

TABLE 1

Studies That Reported the Incidence of Extended-Spectrum β-Lactamase (ESBL) Infections

NOTE. KLEB, Klebsiella species; CLABSI, central line-associated bloodstream infections; CAUTI, catheter-associated urinary tract infection; VAP, ventilator-associated pneumonia.

Incidence of ESBL-Producing E. coli and Klebsiella Infections Among All Patients

Incidence rates varied by year, population, and denominator (ie, patient days, device days, discharges, admissions, infants, and person years). Overall, from 1997 to 2011, incidence rates ranged from 0 to 51 cases per 10,000 admissions. During 1999–2006, incidence rates increased from 8.55 to 16.64 cases for ESBL-Klebsiella infections per 10,000 discharges (P<0.05) among patients admitted to 15 hospitals in Brooklyn, New York.Reference Landman, Bratu and Kochar 20 Throughout 2005–2009, the incidence rate of ESBL-E. coli infections increased from 5.82 to 21.53 cases per 100,000 person years within Olmsted County, Minnesota.Reference Swami, Liesinger, Shah, Baddour and Banerjee 25 From 2005 to 2008, incidence rates significantly increased among patients with ESBL-E. coli infections (range, 0–1.203 cases per 10,000 patient days; P<.001) but not for ESBL-Klebsiella infections (range, 0.837–1.011 per 10,000 patient days; P=0.785) among patients admitted to 16 community hospitals in North Carolina.Reference Freeman, Sexton and Anderson 17 Among 3 hospitals within the University of Pennsylvania Health System, a statistically significant increase in incidence rates were observed among patients with ESBL-E. coli or ESBL-Klebsiella infections after implementing the screening of urine cultures with E. coli or Klebsiella for ESBL (range during 2005–2009, 1.42–2.16 cases per 10,000 patient days preintervention and postintervention periods; P=.006).Reference Han, Bilker and Nachamkin 18

Conversely, from 1997 to 2002, Lipworth et alReference Lipworth, Hyle and Fishman 22 reported a decrease in the incidence rate of ESBL-E. coli and ESBL-Klebsiella infections in 2 university-affiliated hospitals (Hospital A, 4.2–2.3 per 10,000 patient days; Hospital B, 4.5–3.5 per 10,000 patient days).Reference Lipworth, Hyle and Fishman 22 However, the studies by Han et alReference Han, Bilker and Nachamkin 18 and Lipworth et alReference Lipworth, Hyle and Fishman 22 focused on interventions targeting ESBL infections as the outcome. Lipworth et al implemented an antimicrobial formulary, whereas Han et al implemented a hospitalwide urine culture screening protocol.

Incidence of ESBL-Producing E. coli and Klebsiella Infections by Age

Of the 9 studies reviewed, 2 focused on infections in neonates,Reference Larson, Cimiotti and Haas 21 , Reference Stoll, Hansen and Higgins 24 whereas the other 7 studies did not target a specific age group. These studies found that the incidence of ESBL-E. coli infections ranged from 0 to 1.67 per 10,000 infants (Table 1).Reference Larson, Cimiotti and Haas 21 , Reference Stoll, Hansen and Higgins 24 Larson et alReference Larson, Cimiotti and Haas 21 reported zero ESBL-K. oxytoca infections and an incidence of ESBL-K. pneumoniae infections of 51.11 per 10,000 admissions.

Swami et alReference Swami, Liesinger, Shah, Baddour and Banerjee 25 stratified the incidence rates by age for 2005–2009 and found statistically significant trends in incidence over time for patients with ESBL-E. coli infections in the 18–64-year group (range, 7–15 cases per 100,000 person years; P=.03) and the 65–79-year group (range, 28–73 cases per 100,000 person years; P=.02), but they did not find a significant increase in the 0–17-year group (range, 3–8 cases per 100,000 person years; P=.43) or the >80-year group (range, 84–91 cases per 100,000 person years; P=.97).Reference Swami, Liesinger, Shah, Baddour and Banerjee 25

Community-Onset Versus Hospital-Onset ESBL Infections

Definitions for community-onset infections and hospital-onset infections varied by study (Table 2). Of the 6 studies that defined community-onset and hospital-onset infections, 1 study defined hospital-onset infection as an infection occurring >72 hours after admission, while 3 other studies defined this as infections occurring >48 hours after admission. In addition, 2 studies used the National Healthcare Safety Network definitions for device-associated infections (≥3 days after admission). Furthermore, 2 studies differentiated between healthcare-associated infections and hospital-onset infections, while the other 4 studies did not.

TABLE 2

Definitions of Community-Onset Infections and Hospital-Onset Infections

NOTE. N/A, not available; LTCF, long-term-care facility.

Among device-related hospital-onset infections reported to the National Healthcare Safety Network in 2006–2007, the incidence rates of extended-spectrum cephalosporin-resistant infections were 0.064 cases per 1,000 device days for ventilator-associated pneumonia, 0.061 cases per 1,000 device days for catheter-associated urinary tract infections, and 0.051 cases per 1,000 device days for catheter-associated bloodstream infections.Reference Hidron, Edwards and Patel 19 Soe et alReference Soe, Edwards, Sievert, Ricks, Magill and Fridkin 23 used National Healthcare Safety Network data from 2011 to report incidence rates of central-line–associated bloodstream infections from intensive care units within 25 US states. The incidence by state ranged from 0 to 0.37 infections per 1,000 central-line days.Reference Soe, Edwards, Sievert, Ricks, Magill and Fridkin 23 Among patients from community hospitals in North Carolina, most of both the ESBL-E. coli (82.7%) and ESBL-Klebsiella (71.1%) infections were community-onset infections, and approximately half of the patients in each group were nursing home residents (ESBL-E. coli, 51.9%; ESBL-Klebsiella, 50.0%).Reference Freeman, Sexton and Anderson 17 From 2005 to 2009, Han et alReference Han, Bilker and Nachamkin 18 did not observe a significant difference in hospital-onset ESBL-E. coli and ESBL-Klebsiella infections (1.08–1.23 cases per 10,000 patient days; P=.51), even though this study focused on an intervention to reduce hospital-onset infection rates, perhaps the increased rate was due to the intense screening of the urine samples.Reference Han, Bilker and Nachamkin 18 Similarly, during that same period, Swami et alReference Swami, Liesinger, Shah, Baddour and Banerjee 25 did not observe a significant difference in either hospital-onset (range, 0–1 per 100,00 person-years; P=.98) or hospital-associated (range, 4–7 per 100,00 person years; P=.14) ESBL-E. coli bacteriuria rates. However, a significant difference was observed for community-onset ESBL infections (range, 6–14 per 100,000 person years; P=.01).Reference Swami, Liesinger, Shah, Baddour and Banerjee 25

DISCUSSION

This systematic literature review examined the incidence of ESBL-E. coli and ESBL-Klebsiella infections among the US population. Even with an increasing trend, incidence rates varied among the included studies. The variation is potentially due to differences in defining ESBL-producing organisms. Identifying true ESBL incidence rates can be challenging because laboratories need to specifically test for ESBLs, which may not occur on all E. coli and Klebsiella isolates and may vary throughout the study period. Second, inconsistencies existed among the patient populations included in the studies. Some of the studies examined neonates, while others included older adults. Furthermore, the populations included were from various regions throughout the United States. Castanheira et alReference Castanheira, Farrell, Krause, Jones and Sader 26 also found differences in rates between US census regions when examining the proportion of ESBL-E. coli or ESBL-Klebsiella pneumonia over all E. coli or Klebsiella pneumonia isolates.Reference Castanheira, Farrell, Krause, Jones and Sader 26 For E. coli, ESBL rates ranged from 5.2% to 20.1%, and for Klebsiella pneumonia, rates ranged from 3.2% to 34.7%, with the lowest rates reported in the West North Central region and the highest rates in the Mid-Atlantic region.Reference Castanheira, Farrell, Krause, Jones and Sader 26

Many articles were excluded from our systematic literature review because they did not report an appropriate denominator to calculate incidence rates. Instead, these studies reported the proportion of isolates that were identified as ESBL-producing among the total number of isolates for that organism (eg, resistance rates). Thus, without uninfected population denominators, increases in ESBL might be due to increases in ESBL producers, all strains of that organism or both. Therefore, only estimates with population-level denominators that include uninfected patients accurately report incidence rates.

In general, ESBL infections have increased from 1997 to 2011, with a slightly higher incidence rate for ESBL-Klebsiella infections compared with ESBL-E. coli infections. Other studies not included in this systematic literature review also reported increased ESBL infections when examining the proportion E. coli and Klebsiella that are ESBL producing. The SENTRY Antimicrobial Surveillance Program reported the ESBL phenotype in 7% of the 2,768 Klebsiella isolates tested in 1997–2000 from 30 US hospitals.Reference Jones, Biedenbach and Gales 12 In 2011–2013, the proportion of Klebsiella isolates with an ESBL phenotype increased to 15% (840 of 5,580) among isolates collected from 79 US hospitals.Reference Castanheira, Mills, Costello, Jones and Sader 13 Among E. coli isolates, 2 national surveillance programs (SENTRY Antimicrobial Surveillance Program and The Surveillance Network) reported a proportion of ESBL phenotype isolates around 1%–8% in 1997–2000, while in 2011–2013, the International Network for Optimal Resistance Monitoring program reported an increased proportion of 12% among isolates collected from US hospitals.Reference Castanheira, Mills, Costello, Jones and Sader 13 – Reference Karlowsky, Jones, Mayfield, Thornsberry and Sahm 15

Studies included in our analysis reported statistically significant increasing incidence rates for community-onset ESBL infections, while this was not frequently observed among hospital-onset ESBL infections.Reference Han, Bilker and Nachamkin 18 , Reference Swami, Liesinger, Shah, Baddour and Banerjee 25 A recent systematic review of the prevalence of ESBL fecal colonization among healthy individuals reported 14% colonization worldwide, with a 2% rate in the Americas.Reference Karanika, Karantanos, Arvanitis, Grigoras and Mylonakis 27 Therefore, ESBL infections may be increasing more rapidly within the community setting. However, the definitions of community-onset infections and hospital-onset infections differed throughout the studies, making direct comparisons difficult.

This study had several limitations. First, the quality of any systematic literature review is reflected by the conditions of the studies included. Second, publication bias may be present because studies that reported an increase in ESBL infection rates may be more likely to be published compared with studies that found no change. In addition, we only included studies from the United States; therefore, our results may not be generalizable to other countries.

In conclusion, the incidence rates of ESBL-E. coli and ESBL-Klebsiella infections are increasing throughout the United States. These findings may inform empiric antimicrobial treatment, and tracking the emergence of these infections is critically important for guiding antimicrobial stewardship and infection control programs. ESBL-containing bacteria are important targets for emerging state and national surveillance systems and multicenter or nationwide studies are needed to estimate current incidence rates. Without proper estimates for the burden of ESBL infections and other multidrug-resistant pathogens, it remains difficult to appropriately target research and prevention efforts.

ACKNOWLEDGMENTS

Financial support. The study was funded by Centers for Disease Control and Prevention, Safe Healthcare, Epidemiology, and Prevention Research Development (SHEPheRD) Program (contract 200-2011-42039 to M.S. and E.N.P.), by the VA Health Services Research and Development (HSR&D) Career Development Awards (award 11-215 to M.L.S. and award CDA 11-210 to R.N.), and by the CADRE Centers of Innovation (COIN) (grant nos. I50HX001240 and I50HX001242).

Potential conflicts of interest. All authors report no conflicts of interest relevant to this article.

SUPPLEMENTARY MATERIAL

To view supplementary material for this article, please visit https://doi.org/10.1017/ice.2017.156

Footnotes

a

(Present affiliation: Ruth Lilly Medical Library, Indiana University School of Medicine, Indianapolis, Indiana [A.E.B.].).

PREVIOUS PRESENTATION: These data were presented in part at the Society for Healthcare Epidemiology of America 2015 Spring Conference in Orlando, Florida, on May 15, 2015.

References

REFERENCES

1. Jacoby, GA, Medeiros, AA, O’Brien, TF, Pinto, ME, Jiang, H. Broad-spectrum, transmissible beta-lactamases. N Engl J Med 1988;319:723–724.Google Scholar
2. Quinn, JP, Miyashiro, D, Sahm, D, Flamm, R, Bush, K. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989;33:1451–1456.Google Scholar
3. Bush, K. Extended-spectrum beta-lactamases in North America, 1987–2006. Clinical Microbiology Infection 2008;14(Suppl 1):134–143.6.Google Scholar
4. Sader, HS, Jones, RN, Gales, AC, et al. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study Group. Diagn Microbiol Infect Dis. 1998(32):289–301.Google Scholar
5. Shen, D, Biedenbach, DJ, Winokur, PL, Pfaller, MA, Jones, RN. Phenotypic and genotypic characterizations of Chinese strains of Escherichia coli producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 1999;34:159–164.Google Scholar
6. Johnson, DM, Biedenbach, DJ, Jones, RN. In vitro evaluation of broad-spectrum beta-lactams in the Philippines medical centers: role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999;35:291–297.Google Scholar
7. Gales, AC, Bolmstrom, A, Sampaio, J, Jones, RN, Sader, HS. Antimicrobial susceptibility of Klebsiella pneumoniae producing extended-spectrum beta-lactamase (ESBL) isolated in hospitals in Brazil. Braz J Infect Dis 1997;1:196–203.Google ScholarPubMed
8. Bell, JM, Turnidge, JD, Gales, AC, Pfaller, MA, Jones, RN, Sentry APAC Study Group. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998–99). Diagn Microbiol Infect Dis 2002;42:193–198.Google Scholar
9. Einhorn, AE, Neuhauser, MM, Bearden, DT, Quinn, JP, Pendland, SL. Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes. Pharmacotherapy 2002;22:14–20.CrossRefGoogle ScholarPubMed
10. Rice, LB. Successful interventions for gram-negative resistance to extended-spectrum beta-lactam antiobiotics. Pharmacotherapy 1999;19:120S–128S; discussion 133S–137S.Google Scholar
11. Pitout, JDD. Enterobacteriaceae that produce extended-spectrum β-lactamases and AmpC β-lactamases in the community: the tip of the iceberg? Cur Pharm Des 2013;19:257–263.Google Scholar
12. Jones, RN, Biedenbach, DJ, Gales, AC. Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997–2000). Int J Antimicrob Agents 2003;21:1–7.Google Scholar
13. Castanheira, M, Mills, JC, Costello, SE, Jones, RN, Sader, HS. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from US hospitals (2011 to 2013) and characterization of β-lactamase-producing strains. Antimicrob Agents Chemother 2015;59:3509–3517.Google Scholar
14. Winokur, PL, Canton, R, Casellas, JM, Legakis, N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific Region. Clin Infect Dis 2001;32:S94–S103.Google Scholar
15. Karlowsky, JA, Jones, ME, Mayfield, DC, Thornsberry, C, Sahm, DF. Ceftriaxone activity against gram-positive and gram-negative pathogens isolated in US clincial microbiology laboratories from 1996 to 2000: results from The Surveillance Network Database-USA. Int J Antimicrob Agents 2002;19:413–426.Google Scholar
16. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–605.Google Scholar
17. Freeman, JT, Sexton, DJ, Anderson, DJ. Emergence of extended-spectrum beta-lactamase-producing Escherichia coli in community hospitals throughout North Carolina: a harbinger of a wider problem in the United States? Clin Infect Dis 2009;49:e30–e32.Google Scholar
18. Han, JH, Bilker, WB, Nachamkin, I, et al. The effect of a hospital-wide urine culture screening intervention on the incidence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. Infect Control Hosp Epidemiol 2013;34:1160–1166.Google Scholar
19. Hidron, AI, Edwards, JR, Patel, J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 2008;29:996–1011.CrossRefGoogle Scholar
20. Landman, D, Bratu, S, Kochar, S, et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother 2007;60:78–82.Google Scholar
21. Larson, EL, Cimiotti, JP, Haas, J, et al. Gram-negative bacilli associated with catheter-associated and non–catheter-associated bloodstream infections and hand carriage by healthcare workers in neonatal intensive care units. Pediatr Crit Care Med 2005;6:457–461.Google Scholar
22. Lipworth, AD, Hyle, EP, Fishman, NO, et al. Limiting the emergence of extended-spectrum beta-lactamase-producing enterobacteriaceae: influence of patient population characteristics on the response to antimicrobial formulary interventions. Infect Control Hosp Epidemiol 2006;27:279–286.Google Scholar
23. Soe, MM, Edwards, JR, Sievert, DM, Ricks, PM, Magill, SS, Fridkin, SK. Evaluting state-specific antibiotic resitance mesure derived from central line-associated bloodstream infetions, National Healthcare Safety Network, 2011. Infect Control Hosp Epidemiol 2015;36:54–64.Google Scholar
24. Stoll, BJ, Hansen, NI, Higgins, RD, et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002–2003. Pediatr Infect Dis J 2005;24:635–639.CrossRefGoogle Scholar
25. Swami, SK, Liesinger, JT, Shah, N, Baddour, LM, Banerjee, R. Incidence of antibiotic-resistant Escherichia coli bacteriuria according to age and location of onset: a population-based study from Olmsted County, Minnesota. Mayo Clinic Proc 2012;87:753–759.Google Scholar
26. Castanheira, M, Farrell, SE, Krause, KM, Jones, RN, Sader, HS. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine US regions and ceftrazidime-avibactam activiety tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 2014;58:833–838.Google Scholar
27. Karanika, S, Karantanos, T, Arvanitis, M, Grigoras, C, Mylonakis, E. Fecal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk factors among healthy individuals: a systematic review and meta-analysis. Clin Infect Dis 2016;63:310–318.Google Scholar
Figure 0

FIGURE 1Flow diagram of searched studies.

Figure 1

TABLE 1Studies That Reported the Incidence of Extended-Spectrum β-Lactamase (ESBL) Infections

Figure 2

TABLE 2Definitions of Community-Onset Infections and Hospital-Onset Infections

Supplementary material: File

McDanel supplementary material

Appendix

Download McDanel supplementary material(File)
File 43.3 KB